New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
1. High-dose icosapent ethyl reaffirmed as Class IIA therapy for high-risk patients. 2. REDUCE-IT trial's sub-analyses show significant reductions in cardiovascular events. 3. Icosapent ethyl reduces CVD risk in metabolic syndrome patients without diabetes. 4. Data supports Icosapent ethyl's role against lipid-driven cardiovascular risk. 5. VASCEPA has been prescribed over 25 million times, enhancing clinical visibility.